Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Intellia Therapeutics, Inc. (NTLA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M | — |
| Research & development | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M | $150.4M | $108.4M | $89.1M | $67.6M | $31.8M | $11.2M |
| Operating income | −$441.0M | −$534.3M | −$515.3M | −$458.2M | −$267.9M | −$136.6M | −$106.4M | −$90.9M | −$69.6M | −$32.2M | −$13.4M |
| EBITDAderived | −$431.2M | −$524.0M | −$506.3M | −$450.6M | −$261.0M | −$130.3M | −$100.8M | −$86.4M | −$66.6M | −$31.1M | −$13.1M |
| Net income | −$412.7M | −$519.0M | −$481.2M | −$474.2M | −$267.9M | −$134.2M | −$474.2M | −$85.3M | −$67.5M | −$31.6M | −$12.4M |
| Basic EPSper diluted share | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 | -$2.40 | -$2.11 | -$1.98 | -$1.88 | -$1.42 | -$51.02 |
| Diluted EPSper diluted share | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 | -$2.40 | -$2.11 | -$1.98 | -$1.88 | -$1.42 | -$51.02 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 2, 2026Form 4 | BASTA JAMESEVP, General Counsel | SellCommon Stock | 1.2K | $13.78 | $16.7K | 156.8K |
| Mar 2, 2026Form 4 | Clark ElianaEVP, Chief Technical Officer | SellCommon Stock | 607 | $13.78 | $8.4K | 93.9K |
| Jan 5, 2026Form 4 | LEONARD JOHN MPresident and CEO | SellCommon Stock | 34.1K | $9.21 | $314.5K | 1.01M |
| Jan 5, 2026Form 4 | Schultes Birgit CEVP, Chief Scientific Officer | SellCommon Stock | 8.5K | $9.21 | $78.4K | 98.5K |
| Jan 5, 2026Form 4 | BASTA JAMESEVP, General Counsel | SellCommon Stock | 10.4K | $9.21 | $95.8K | 101.5K |